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ABSTRACT  We investigated the efficacy of intravenous penicillin (sulbactam/ampicillin: 
SBT/ABPC) in adult patients with positive Streptococcus pneumoniae urinary antigen test 
requiring hospitalization. We administered 3g of SBT/ABPC intravenously in the morning and 
evening for 7-14 days to 32 adult community-acquired pneumonia patients with positive  Binax 
NOW® S. pneumoniae urinary antigen.  Clinical efficacy, bacteriological efficacy, and side 
effects of these patients were prospectively examined. We observed clinical efficacy in a total 
of 28 of 32 patients (87.5%); 24 of 26 moderate patients (92.3%), and four of six severe patients 
(66.7%). Side effects were drug eruption, increased GOT, increased AMY, and decreased 
WBC, observed in one patient each; however, all were mild. SBT/ABPC is extremely useful in 
patients with positive S. pneumoniae urinary antigen test requiring hospitalization
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INTRODUCTION
　The JRS guidel ines for  the management 
of community-acquired pneumonia in adults 
recommend in t ravenous  penic i l l in  dr ip  i f 
Streptococcus pneumoniae urinary antigen test 
shows positive. Therefore, we examined the clinical 
efficacy of intravenous penicillin (sulbactam/
ampicillin: SBT/ABPC) in patients with adult 
community-acquired pneumonia and positive 
S. pneumoniae urinary antigen test requiring 
hospitalization.
SUBJECTS AND METHODS
Subjects 
　Subjects were 32 patients with adult community-
acquired pneumonia and positive S. pneumoniae 
urinary antigen test who underwent treatment at 
Kawasaki Hospital, Kawasaki Medical School from 
January 2009 through December 2011.
Methods 
　Adult community-acquired pneumonia patients 
with positive urinary antigen for S.pneumoniae 
(Binax NOW® S. pneumoniae) were administered 
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3g of SBT/ABPC intravenously in the morning 
and evening for 7-14 days. Then clinical efficacy, 
bacteriological efficacy, and side effects of these 
patients were prospectively examined. This study 
was approved by the clinical trial review committee 
of our institution.
RESULTS
Subjects (Table1)
　Subjects were 20 males and 12 females aged 40 
to 91 years (72.8±15.5 years).
　Severity by A-DROP system was moderate in 26 
patients and severe in 6 patients.
Underlying disease (Table2)
　COPD (chronic obstructive pulmonary disease) 
was observed in four subjects, bronchial asthma 
in three, bronchiectasis in three, cerebrovascular 
diseases in five, hypertension in five, diabetes 
mellitus in three, and hypothyroidism in one. 
Clinical efficacy (Table3)
　Clinical efficacy was observed in a total of 28 
of 32 (87.5%) patients; 24 of 26 (92.3%) moderate 
patients, and in four of six (66.7%) severe patients. 
Efficacy was observed in three patients (PISP two, 
PRSP one) with penicillin-resistant S. pneumoniae. 
With regard to sensitivity of penicillin-G , MIC ≦2
μg , MIC ＝4μg , and MIC ≧8μg were judged 
as PSSP, PISP, and PRSP, respectively. 
Bacteriological efficacy (Table 4)
　PSSP 19 strains, PISP two strains, and PRSP one 
strain were isolated, and all were eradicated. 
Side effects (Table 5)
　Clinical adverse reaction was drug eruption in 
one patient (3.1%). Abnormal laboratory findings 
were increased GOT, increased AMY, and decreased 
WBC in one patient each; however, all were mild, 
and there were no patients whose treatment was 
discontinued, or who received treatment for adverse 
effects.    
DISCUSSION
　S. pneumoniae is the most frequently observed 
microorganism in adult community-acquired 
pneumonia, accounting for 25-39% of patients with 
pneumonia requiring hospitalization. Pneumonia 
caused by S. pneumoniae is a potentially-severe 
pneumonia1).
　Gram staining and culture are useful in diagnosis. 
Recently, S. pneumoniae urinary antigen test has 
been widely used in the clinical setting for rapid 
diagnosis. The JRS guidelines for the management 
of community-acquired pneumonia in adults 
Table 1. Subjects
　　No.  of   patients
　　  AGE （years）
　　Severity
　　　Moderate
　　　Severe
   32    （M 20 : F 12）
40-91（72.8 ± 15.5）
   26
    6
Table 2. Underlying diseases
　Respiratory diseases 10　
　　Chronic obstructive pulmonary disease 4
　　Bronchial asthma 3
　　Bronchiectasis 3
　Cerebrouasmlar diseases 5　
　Hypertension 5　
　Diabets mellitus 3　
　Hypothyroidism 1　
　None 8　
Table 3. Clinical efﬁcacy
Severity Good Poor Efﬁcacy rate (%)
Moderate: 26 24 (1) 2 92.3
Severe　 : 6 4 (2) 2 66.7
Total　　: 32 28 4 87.5
　　　　　　　　　　　　　　　　　　　　　　（1）PISP
　　　　　　　　　　　　　　　　　　　　　　（2）PRSP
Table 4. Bacteriological efﬁcacy
No. of strains Eradicated Eradication rate (%)
PSSP 19 19
PISP 2 2
PRSP 1 1
Total 22 22 100%
Table 5. Side effects
Clinical adverse reaction Drug eruption 　1　
　（1 / 32 ＝ 3.1%）
Abnormal laboratory ﬁndings GOT　↑ 1　
Amy　 ↑ 1　
WBC　↓ 1　
　（3 / 32 ＝ 9.3%）
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recommend S. pneumoniae urinary antigen test to 
identify the causative organism. S. pneumoniae 
urinary antigen test (Binax NOW® S. pneumoniae) 
is the method to detect urinary capsule antigen for 
S. pneumoniae by immunochromatography. It has 
higher sensitivity than sputum or blood culture, 
with a sensitivity of 70-80% and a specificity of 80- 
90%2-5). The JRS guidelines also recommend 
intravenous penicillin for patients with positive 
S. pneumoniae urinary antigen test requiring 
hospitalization. 
　Therefore ,  we evaluated the eff icacy of 
intravenous penicillin (sulbactam/ampicillin: SBT/
ABPC) in patients with positive S. pneumoniae 
urinary antigen test requiring hospitalization. SBT/
ABPC is ABPC compounded with a β-lactamase 
inhibitory agent that exhibits a strong antibacterial 
effect against S. pneumoniae. 
　Subjects were 26 moderate and 6 severe patients 
aged 40 to 91 years (72.8±15.5years). Many 
patients had underlying respiratory diseases such 
as COPD, bronchial asthma, or bronchiectasis, 
suggesting that pneumonia caused by S. pneumoniae 
tends to occur in elderly individuals with chronic 
respiratory diseases. 
　Studies on the effect of SBT/ABPC on adult 
community-acquired pneumonia include an 
investigation by Williams et al.6) reporting a higher 
efficacy than cefamandole in 36 of 37 (97%) 
patients, and an investigation by Seki et al.7) 
reporting the same degree of efficacy as PIPC in 
33 of 49 (67.3) patients. Studies on community-
acquired pneumonia in the elderly include our 
report8) of efficacy in 64 of 83 (77.1%) patients 
aged 75 years or greater, and an investigation by 
Yanagihara et al.9) describing the same efficacy as 
IPM/CS in 32 of 35 (91.4%) patients aged 65 years 
or greater. 
　The present investigation of community-acquired 
pneumonia caused by S. pneumoniae alone revealed 
an excellent clinical effect with efficacy in 28 of 
32 (87.5%) patients; 24 of 26 (92.3%) moderate 
patients, and four of six (66.7%) severe patients. 
Furthermore, in terms of bacteriology, all strains 
composed of PSSP (19 strains), PISP (two strains), 
and PRSP (one strain) were eradicatd.
　Although the MIC of penicillin-G was as high as 
4μｇ10) for PISP and PRSP, administration of 3 g 
of SBT/ABPC b. i. d. was efficacious for penicillin-
resistant S.pneumoniae. 
　Side effects were drug eruption, increased GOT, 
increased AMY, and decreased WBC in one patient 
each; however, all were mild, showing high safety. 
The results of Metaanalysis11) also showed high 
safety. 
　As shown above,  in t ravenous penici l l in 
(sulbactam/ampicillin: SBT/ABPC) for patients 
with positive S. pneumoniae urinary antigen test 
requiring hospitalization is extremely useful. 
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